|
|
 |
|
Viewing report
|
|
|
|
Autoimmune Market Forecast to 2014
Cutting Edge Information, June 2009, Pages: 293
If your company is looking to build or vitalize presence in the competitive autoimmune market, you’ll need a tool to give you unshakeable confidence in your decision-making. Autoimmune Market Forecast to 2014 is your all-in-one, comprehensive resource for the most current data available on autoimmune products, drug classes and manufacturers. Expert analysis will help you identify and capitalize on opportunities to chart a clear, profitable course through the market space.
Other reports cover one or two autoimmune indications or only the top drugs at the top companies. Ours covers products for six major conditions psoriasis, lupus, rheumatoid arthritis, Crohn’s disease, ulcerative colitis and multiple sclerosis at different stages of development. Our data analyses are integrated so you understand the contexts and implications that impact the whole market.
Within the report, you’ll find:
- indication history, epidemiology and treatment options
- the brands and drug classes poised to dominate the market
- and those vulnerable
- clinical trial information
- novel therapies -and their status toward market
- autoimmune company strengths, weaknesses, threats and opportunities, how does your company rank among others in this market?
We’ve done the hard work of sifting through and vetting the most relevant data so you don’t have to. Go ahead and be bold, knowing that you’re making smart choices. Use this report today for an immediate impact!
Report Covers:
Product Breakdown:
- 43 Profiled Drugs
- 23 Biologics
- 20 Small Molecules
- 6 Indications
Brand Profile Components:
- Product history
- Competitive and strategic positioning
- Market growth opportunities
- Sales projection charts
- Materiality charts
- Approval histories
- Market exclusivity and patent information (for approved drugs)
- Clinical trial data tables
Company Profile Components:
- Autoimmune market ranking
- Strengths analysis
- Growth areas analysis
- Key products breakdown
Customers who bought this item also bought
Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success
The Future of Autoimmune Diseases Therapeutics – Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deal Analysis
Special Report: The Autoimmune Biologics Pipeline-A Competitive Review
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
Use of Biomarkers to Predict Response to Biologics Therapy in Autoimmune Diseases
Clinical Trial Recruitment in Autoimmune Disorders-Average Patient Recruitment Per Trial has Continued to Decline Over the Past Decade
Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market
Competitor Analysis - Antibody Therapy of Inflammatory and Autoimmune Diseases
The Immunomodulators Market Outlook to 2016
Strategic Overview of the Autoimmune Biologics Market
|
|
|
|
